Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose decitabine plus venetoclax maintenance after allogeneic stem cell transplantation for acute leukemia/myelodysplastic syndrome
ChiCTR1900025374Phase 2Recruiting
- Sponsor
- Tianjin First Central Hospital
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of decitabine and venetoclax in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Tianjin First Central Hospital. Primary endpoints: Complete remission state of bone marrow, Remission state of hematology and 3 more. Started Aug 2019; status: recruiting.
02
Drugs
decitabinevenetoclax
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR1900025374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025374.